 Connection
Co-Authors
This is a "connection" page, showing publications co-authored by Peter Kabos and Christine Fisher.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
1.164 |
|
|
|
-
Sakamoto MR, Eguchi M, Azelby CM, Diamond JR, Fisher CM, Borges VF, Bradley CJ, Kabos P. New Persistent Opioid and Benzodiazepine Use After Curative-Intent Treatment in Patients With Breast Cancer. J Natl Compr Canc Netw. 2021 01 06; 19(1):29-38.
Score: 0.191
-
Stumpf PK, Cittelly DM, Robin TP, Carlson JA, Stuhr KA, Contreras-Zarate MJ, Lai S, Ormond DR, Rusthoven CG, Gaspar LE, Rabinovitch R, Kavanagh BD, Liu A, Diamond JR, Kabos P, Fisher CM. Combination of Trastuzumab Emtansine and Stereotactic Radiosurgery Results in High Rates of Clinically Significant Radionecrosis and Dysregulation of Aquaporin-4. Clin Cancer Res. 2019 07 01; 25(13):3946-3953.
Score: 0.169
-
Stokes WA, Amini A, Jackson MW, Plimpton SR, Kounalakis N, Kabos P, Rabinovitch RA, Rusthoven CG, Fisher CM. Patterns of Fractionation and Boost Usage in Adjuvant External Beam Radiotherapy for Ductal Carcinoma in Situ in the United States. Clin Breast Cancer. 2018 06; 18(3):220-228.
Score: 0.150
-
Jasem J, Fisher CM, Amini A, Shagisultanova E, Rabinovitch R, Borges VF, Elias A, Kabos P. The 21-Gene Recurrence Score Assay for Node-Positive, Early-Stage Breast Cancer and Impact of RxPONDER Trial on Chemotherapy Decision-Making: Have Clinicians Already Decided? J Natl Compr Canc Netw. 2017 04; 15(4):494-503.
Score: 0.147
-
Jasem J, Amini A, Rabinovitch R, Borges VF, Elias A, Fisher CM, Kabos P. 21-Gene Recurrence Score Assay As a Predictor of Adjuvant Chemotherapy Administration for Early-Stage Breast Cancer: An Analysis of Use, Therapeutic Implications, and Disparity Profile. J Clin Oncol. 2016 06 10; 34(17):1995-2002.
Score: 0.137
-
Jasem J, Altoos B, Fisher CM, Elias AD, Kounalakis N, Borges VF, Kabos P. Multiple Hepatic Lesions in a Patient With a History of DCIS. Oncology (Williston Park). 2015 Sep; 29(9):669-70, 678-9.
Score: 0.132
-
Travers SS, Fisher CM, Kabos P, Cittelly DM, Ormond DR. Breast cancer brain metastases localization and risk of hydrocephalus: a single institution experience. J Neurooncol. 2023 May; 163(1):115-121.
Score: 0.056
-
Schreiber AR, Kagihara J, Eguchi M, Kabos P, Fisher CM, Meyer E, Molina E, Kondapalli L, Bradley CJ, Diamond JR. Evaluating anthracycline?+?taxane versus taxane-based chemotherapy in older women with node-negative triple-negative breast cancer: a SEER-Medicare study. Breast Cancer Res Treat. 2022 Jan; 191(2):389-399.
Score: 0.051
-
Stoen E, Kagihara J, Shagisultanova E, Fisher CM, Nicklawsky A, Kabos P, Borges VF, Diamond JR. Real-world evidence from a University Hospital system regarding the uptake of adjuvant pertuzumab and/or neratinib before and after their FDA approval. Breast Cancer Res Treat. 2021 Jun; 187(3):883-891.
Score: 0.048
-
Weiss JA, Nicklawsky A, Kagihara JA, Gao D, Fisher C, Elias A, Borges VF, Kabos P, Davis SL, Leong S, Eckhardt SG, Diamond JR. Clinical outcomes of breast cancer patients treated in phase I clinical trials at University of Colorado Cancer Center. Cancer Med. 2020 12; 9(23):8801-8808.
Score: 0.047
-
Overholser L, Shagisultanova E, Rabinovitch RA, Kounalakis N, Diamond J, Finlayson CA, Fisher CM, Kabos P, Elias AD, Borges VF, Mayordomo J. Breast Cancer Following Radiation for Hodgkin Lymphoma: Clinical Scenarios and Risk-Reducing Strategies. Oncology (Williston Park). 2016 12 15; 30(12):1063-70.
Score: 0.036
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|